1254205-52-1

Basic information

• Product Name: RQ-00203078
• Synonyms: RQ-00203078;4-[[[3-Chloro-5-(trifluoromethyl)-2-pyridinyl][[4-(trifluoromethoxy)phenyl]methyl]amino]sulfonyl]benzoic acid
• CAS NO: 1254205-52-1
• Molecular Formula: C₂₁H₁₃ClF₆N₂O₅S
• Molecular Weight: 554.8467392
• Product Categories: Inhibitors
• Mol File: 1254205-52-1.mol

Chemical Properties

• Boiling Point: 602.0±65.0 °C(Predicted)
• Appearance: /
• Density: 1.588±0.06 g/cm3(Predicted)
• Solubility: insoluble in H2O; ≥18.85 mg/mL in DMSO; ≥27.25 mg/mL in EtOH
• PKA: 3.39±0.10(Predicted)
• CAS DataBase Reference: RQ-00203078(CAS DataBase Reference)
• NIST Chemistry Reference: RQ-00203078(1254205-52-1)
• EPA Substance Registry System: RQ-00203078(1254205-52-1)

Safety Data

• Hazardous Substances Data: 1254205-52-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
RQ-00203078 is used as a therapeutic agent for targeting TRPM8, which is involved in conditions such as chemotherapy-induced peripheral neuropathy, diabetic neuropathy, migraine, and overactive bladder. Its selective antagonism of TRPM8 may provide relief from cold hyperalgesia and cold allodynia associated with these diseases.
Used in Oncology:
RQ-00203078 is used as an anticancer agent, particularly in the context of oral squamous carcinoma. It has shown potential in reducing cell migration and invasion in vitro, which could contribute to the development of novel treatment strategies for this type of cancer.
Used in Drug Development:
RQ-00203078 serves as a valuable compound in the development of new drugs targeting TRPM8. Its high selectivity and specificity make it a promising candidate for further research and potential clinical applications in various disease conditions and cancer treatments.

in vitro

in the menthol-induced calcium influx assay, rq-00203078 is a novel and highly potent trpm8 antagonist with human and rat ic50 values of 8.3 nm and 5.8 nm, respectively. rq-00203078 was highly selective over other trp channels [1].

in vivo

rq-00203078 demonstrated excellent activity in vivo in a dose dependent manner with an ed50 value of 0.65 mg/kg in the icilin-induced wet-dog shakes model in rats after oral administration [1].

IC 50

8.3 and 5.8 nm for htrpm8 and rtrpm8, respectively

references

[1] ohmi m, shishido y, inoue t, ando k, fujiuchi a, yamada a, watanabe s, kawamura k. identification of a novel 2-pyridyl-benzensulfonamide derivative, rq-00203078, as a selective and orally active trpm8 antagonist. bioorg med chem lett. 2014 dec 1;24(23):5364-8.

Upstream product

• 1254207-09-4 methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-(trifluoromethoxy)benzyl)sulfamoyl)benzoate 
• 93919-56-3 4-(trifluoromethoxy)benzyl amine 
• 1254207-05-0 methyl 4-(N-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)sulfamoyl)benzoate 
• 69812-51-7 4-chlorosulfonyl-benzoic acid methyl ester 

Relevant articles and documents

Identification of a novel 2-pyridyl-benzensulfonamide derivative, RQ-00203078, as a selective and orally active TRPM8 antagonist

A novel series of 2-pyridyl-benzensulfonamide derivatives have been identified as selective and orally active TRPM8 antagonists via high throughput screening (HTS). Exploration of the structure-activity relationships of compound 1 has led to the identification of RQ-00203078 (compound 36) as a highly selective, potent and orally available TRPM8 antagonist. RQ-00203078 demonstrated excellent in vivo activity in a dose dependent manner with an ED50 value of 0.65 mg/kg in the icilin-induced wet-dog shakes model in rats after oral administration and may become an important pharmacological tool for fully assessing the potential therapeutic use of the targets activated by cold stimulation.

SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS

The present invention relates to sulfamoyl benzoic acid derivatives of formula (I) or a pharmaceutically acceptable salt thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the TRPM8 receptor.